The checklist included reminders for time-sensitive measures.
The topical gel may be suitable for patients who experience gastrointestinal side effects from oral NSAIDs.
Investigational multiple sclerosis drug MD1003 delivers 300 mg/day of biotin, a huge increase the usually recommended dose of 30-100 mcg/day.
Compared with APOE ε4, APOE ε2 seems to have an indirect effect on cognition by influencing AD pathology.
The app's data easily exports so that physicians have access to accurate, long- and short-term outcomes for patients.
Uncertainty about when to order imaging studies, existing guidelines on migraine preventive treatments common.
Common Parkinson's hallucinations replicated using Oculus Rift headset.
30 mg of suvorexant improved PRO and PSG measures of sleep maintenance and sleep onset at the earliest time points.
Those who drank larger amounts of hard alcohol had the strongest association with lower EDSS.
Sleep problems are common in patients with stroke and may contribute to declines in cognitive performance.
Personalized obstetrical care may be warranted during intrapartum period.
Outgoing AAN president Timothy Pedley, MD, spoke of greater utilization of advanced practice professionals to better serve patients.
Speech impairment previously thought irreversible show incremental improvement with the experimental treatment.
Threshold-tracking transcranial magnetic stimulation could be a useful diagnostic technique in the clinical setting.
A topographical model of multiple sclerosis uses animation to illustrate the continuum of the disease.
The positive correlation could mean that migraineurs are unable to direct attention away from painful stimuli.
In-hospital mortality was significantly lower despite longer overall stays.
The well-tolerated treatment helped sustain migraine relief more than 48-hours post-dose.
Total annual healthcare costs per patient increase incrementally with each dose.
Waiting times for assessment were reduced by approximately 70% compared with the standard model.
FDA is reviewing a supplemental new drug application to expand the indication for eslicarbazepine acetate (ESL) as a monotherapy.
Nearly 40% of clinically-stable patients who stopped taking medication recorded a relapse or disability progression.
People with MS that currently use marijuana are likely to report higher levels of disability and more recent relapse.
The EMG device is discreet and easy to wear, weighing only 6.5 ounces.
The guidelines encourage doctors to have a meaningful conversation with their patients to evaluate risks and benefits of treatment.
Entire network stimulation may better improve motor excitability vs. primary motor cortex stimulation alone.
Screening for post-concussive psychiatric symptoms could help shorten recovery.
Psychiatric comorbidities, which often aren't diagnosed until teenage years, seemed to attribute to prolonged recoveries.
The news comes after an experimental drug was found to restore myelin in patients with acute optic neuritis.
Natalia Rost, MD, shares her thoughts on the upcoming agenda for AAN 2015.
Neurology Advisor Articles
- Addressing Rare Headache Disorders: Acute Confusional Migraine
- Organic Solvents Plus Genetics May Increase Risk of Multiple Sclerosis
- No Significant Clinical Differences Between Cluster Headaches With and Without Aura
- Co-Prescription of Opioids and Antidepressants Prevalent in Migraine
- Deep Brain Stimulation May Slow Rest Tremor Progression in Parkinson Disease
- Herpesvirus Abundant in Alzheimer Disease Brain, New Study Finds
- Patients' Preferences for Physician Attire Linked to Perception of Care
- Weighing the Risks of Deep Brain Stimulation
- Grey Matter Atrophy Sequence in Multiple Sclerosis Phenotypes
- Higher Vitamin D Levels Associated With Fewer Lesions in Multiple Sclerosis
- Risk Factors for Impulse Control Behaviors in Parkinson Disease
- Cardiac Pathology in SUDEP Compared With Sudden Arrhythmic or Traumatic Deaths
- 11.2% of U.S. Adults Aged ≥45 Report Subjective Mental Decline
- AMA Aims to Boost Affordability of ACA Marketplace Plans
- Conscious Sedation Increases Risk of Poor Functional Outcome, Mortality Following Stroke Treatment